Business Wire

Ooredoo Group Selects P.I. Works as Sole Supplier of Centralized SON Solution

30.1.2018 11:00:00 EET | Business Wire | Press release

Share

P.I. Works, worldwide leading provider of mobile network planning, management and optimization solutions, has been awarded the Ooredoo Group Framework contract to deploy a multi-vendor and multi-technology C-SON (Centralized Self Organizing Networks) solution across its footprint worldwide.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180130005549/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: P.I. Works)

Ooredoo Group is one of the fastest-growing telecommunications companies in the world, with over 150 million customers across its footprint enjoying high-quality mobile services. P.I. Works, with its award-winning C-SON platform uSON, will play an important role in this endeavor of Ooredoo Group with a full-scope C-SON implementation. The project scope includes standard and advanced closed loop SON functions for 2G, 3G and 4G networks. SON will be instrumental in providing Ooredoo Group a competitive edge in its densification strategy. P.I. Works will also provide HetNet aware optimization capabilities as well for improving the performance of both macro-cells and small-cells in the network.

Waleed Al Sayed, Deputy Group Chief Executive Officer, Ooredoo, said: “P.I. Works SON showed by far the best field results in the shortest timeframe in a recent pilot project in Jakarta, Indonesia. We have full confidence in P.I. Works’ multi-vendor, multi-technology SON capabilities. We are confident that this partnership will enable us to enhance our customers’ mobile experience across the markets where we operate and maximize the efficiency of our networks through greater automation.”

P.I. Works CEO and co-founder Başar Akpınar said: “P.I. Works’ vision is to help mobile operators realize the full potential of their networks, so that they can build the hyperconnected world of tomorrow. Our award-winning C-SON solution is already deployed into the networks of the leading Tier 1 operators worldwide. In its endeavor to enrich people’s digital lives, Ooredoo Group will benefit from our worldwide expertise, as P.I. Works is fully committed to helping Ooredoo Group deliver high quality mobile services.”

About Ooredoo Group

Ooredoo is an international communications company operating across the Middle East, North Africa and Southeast Asia. Serving consumers and businesses in 10 countries, Ooredoo delivers the leading data experience through a broad range of content and services via its advanced, data-centric mobile and fixed networks. Ooredoo serves over 150 million customers and generated revenues of QR 33 billion as of 31 December 2016. Its shares are listed on the Qatar Stock Exchange and the Abu Dhabi Securities Exchange.

About P.I. Works

P.I. Works is a leading provider of next-generation mobile network planning, management and optimization solutions. P.I. Works combines field-proven expertise with a commercially available product portfolio and services. These solutions enable Mobile Network Operators to lower their costs and to improve network quality and subscriber experience. P.I. Works has deployed its solutions at more than 30 mobile network operators in 28 countries. P.I. Works also plays an important role in the development of key standards that define the future of mobile networks. P.I. Works contributes actively to the ETSI, GTI, and 3GPP standardization forum.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
P.I. Works
Melih Murat
marketing@piworks.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye